Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib

Proteasomal inhibition revolutionized myeloma therapies in this decade of novel agents. The only US Food and Drug Administration approved proteasome inhibitor so far, bortezomib effectively targets the constitutive proteasome subunit β5 of the 26S proteasome. Bortezomib induces high and quality resp...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Nooka, Ajay, Gleason, Charise, Casbourne, Daniela, Lonial, Sagar
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2013
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3563316/
https://ncbi.nlm.nih.gov/pubmed/23386784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S24580
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller